Patents by Inventor Simona Cotesta

Simona Cotesta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20130281463
    Abstract: The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: October 25, 2011
    Publication date: October 24, 2013
    Applicant: NOVARTIS AG
    Inventors: Sangamesh Badiger, Dirk Behnke, Claudia Betschart, Simona Cotesta, Samuel Hintermann, Silvio Ofner, Chetan Pandit, Bernard Lucien Roy
  • Diaza-spiro[5.5]undecanes
    Patent number: 8530648
    Abstract: The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: September 10, 2013
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Dirk Behnke, Claudia Betschart, Vinod Chaudhari, Simona Cotesta, Jürgen Hans-Hermann Hinrichs, Silvio Ofner, Chetan Pandit, Jürgen Wagner
  • DIAZA-SPIRO[5.5]UNDECANES
    Publication number: 20120264748
    Abstract: The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: December 20, 2010
    Publication date: October 18, 2012
    Applicant: NOVARTIS AG
    Inventors: Sangamesh Badiger, Dirk Behnke, Claudia Betschart, Vinod Chaudhari, Simona Cotesta, Jürgen Hans-Hermann Hinrichs, Silvio Ofner, Chetan Pandit, Jürgen Wagner
  • DISUBSTITUTED HETEROARYL-FUSED PYRIDINES
    Publication number: 20120258973
    Abstract: The invention relates to compound of the formula (I?) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: December 20, 2010
    Publication date: October 11, 2012
    Applicant: NOVARTIS AG
    Inventors: Sangamesh Babiger, Dirk Behnke, Claudia Betschart, Vinod Chaudhari, Murali Chebrolu, Simona Cotesta, Samuel Hintermann, Arndt Meyer, Chetan Pandit
  • Di/tri-aza-spiro-C9-C11alkanes
    Publication number: 20120165331
    Abstract: The invention relates to compounds of the formula I A-D-C(R1)2—B??(I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: December 19, 2011
    Publication date: June 28, 2012
    Inventors: Sangamesh BADIGER, Dirk BEHNKE, Claudia BETSCHART, Vinod CHAUDHARI, Simona COTESTA, Samuel HINTERMANN, Andreas LERCHNER, Fatma LIMAM, Silvio OFNER, Chetan PANDIT, Jürgen WAGNER
  • Diaza-spiro[5.5]undecanes
    Publication number: 20120101110
    Abstract: The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: October 18, 2011
    Publication date: April 26, 2012
    Inventors: Sangamesh BADIGER, Dirk BEHNKE, Claudia BETSCHART, Simona COTESTA, Samuel HINTERMANN, Silvio OFNER, Chetan PANDIT, Bernard Lucien ROY
  • QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE
    Publication number: 20120094958
    Abstract: The invention relates to a compound of formula (I) wherein the substituents are as described in the specification, which are useful as farnesyl pyrophosphate synthase modulators, e.g. in the treatment of proliferative diseases, to methods of manufacturing such compounds and to intermediates thereof.
    Type: Application
    Filed: February 26, 2009
    Publication date: April 19, 2012
    Applicant: NOVARTIS AG
    Inventors: Rene Amstutz, Guido Bold, Simona Cotesta, Wolfgang Jahnke, Andreas Marzinzik, Juliane Constanze Desiree Hartwieg, Silvio Ofner, Frédérik Stauffer, Johann Zimmermann
  • SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS
    Publication number: 20110288057
    Abstract: The invention relates to the use of and mainly novel compounds of the formula I wherein the moieties are as defined in the description, which are useful as farnesyl pyrophosphate synthase modulators and e.g. in the treatment of proliferative diseases.
    Type: Application
    Filed: October 12, 2009
    Publication date: November 24, 2011
    Applicant: Novartis AG
    Inventors: Simona Cotesta, Joseph Fraser Glickman, Wolfgang Jahnke, Andreas Marzinzik, Silvio Ofner, Jean-Michel Rondeau, Thomas Zoller
  • PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS
    Publication number: 20110257131
    Abstract: (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula I, wherein one of R1 and R2 are as defined in the specification, and can be in free form, in the form of an ester, and/or of a salt.
    Type: Application
    Filed: December 21, 2009
    Publication date: October 20, 2011
    Applicant: NOVARTIS AG
    Inventors: Simona Cotesta, Wolfgang Jahnke, Jean-Michel Rondeau, Sven Weiler, Leo Widler
  • C2-C5-Alkyl-Imidazole-Bisphosphonates
    Publication number: 20110224173
    Abstract: C2-C5-Alkyl-substituted [imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.
    Type: Application
    Filed: May 26, 2011
    Publication date: September 15, 2011
    Applicant: NOVARTIS AG
    Inventors: Sven Weiler, Leo Widler, Jean-Michel Rondeau, Simona Cotesta, Wolfgang Jahnke
  • C-C-alkyl-imidazole-bisphosphonates
    Patent number: 7977323
    Abstract: C2-C5-Alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: July 12, 2011
    Assignee: Novartis AG
    Inventors: Sven Weiler, Leo Widler, Jean Michel Rondeau, Simona Cotesta, Wolfgang Jahnke
  • 4-ARYL-BUTANE-1,3-DIAMIDES
    Publication number: 20100222396
    Abstract: The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: January 28, 2010
    Publication date: September 2, 2010
    Applicant: Novartis AG
    Inventors: Dirk BEHNKE, Claudia Betschart, Simona Cotesta, Marc Gerspacher, Samuel Hintermann, Bernard Lucien Roy, Anette Von Matt, Jürgen Wagner
  • C2-C5-Alkyl-Imidazole-Bisphosphonates
    Publication number: 20090143337
    Abstract: C2-C5-Alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.
    Type: Application
    Filed: November 26, 2008
    Publication date: June 4, 2009
    Applicant: NOVARTIS AG
    Inventors: Sven Weiler, Leo Widler, Jean-Michel Rondeau, Simona Cotesta, Wolfgang Jahnke
  • ORGANIC COMPOUNDS
    Publication number: 20090099199
    Abstract: The invention relates to compound of the formula I wherein the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: October 15, 2008
    Publication date: April 16, 2009
    Inventors: Joachim Nozulak, David Orain, Simona Cotesta